{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:19:19Z","timestamp":1792189159700,"version":"4.4.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Marat\u00f3","award":["215\/C\/2021"],"award-info":[{"award-number":["215\/C\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The coronavirus disease 2019 (COVID-19) pandemic revealed that our understanding of infectious complications and strategies to mitigate severe infections in patients with glomerular diseases is limited. Beyond COVID-19, there are several infections that specifically impact care of patients receiving immunosuppressive measures. This review will provide an overview of six different infectious complications frequently encountered in patients with glomerular diseases, and will focus on recent achievements in terms of vaccine developments and understanding of the use of specific antimicrobial prophylaxis. These include influenza virus, Streptococcus pneumoniae, reactivation of a chronic or past infection with hepatitis B virus in cases receiving B-cell depletion, reactivation of cytomegalovirus, and cases of Pneumocystis jirovecii pneumonia in patients with anti-neutrophil cytoplasmic antibody\u2013associated vasculitis. Varicella zoster virus infections are particularly frequent in patients with systemic lupus erythematosus and an inactivated vaccine is available to use as an alternative to the attenuated vaccine in patients receiving immunosuppressants. As with COVID-19 vaccines, vaccine responses are generally impaired in older patients, and after recent administration of B-cell depleting agents, and high doses of mycophenolate mofetil and other immunosuppressants. Strategies to curb infectious complications are manifold and will be outlined in this review.<\/jats:p>","DOI":"10.1093\/ndt\/gfad080","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T11:03:38Z","timestamp":1684839818000},"page":"ii40-ii49","source":"Crossref","is-referenced-by-count":18,"title":["Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6273-7513","authenticated-orcid":false,"given":"Martin","family":"Windpessl","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, Nephrology, Klinikum Wels-Grieskirchen , Wels , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Kostopoulou","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3362","authenticated-orcid":false,"given":"Richard","family":"Conway","sequence":"additional","affiliation":[{"name":"St James's Hospital , Dublin , Ireland"},{"name":"Trinity College Dublin , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-7830","authenticated-orcid":false,"given":"Ilay","family":"Berke","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Marmara University School of Medicine , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-9941","authenticated-orcid":false,"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Department of Health, Medicine and Caring Sciences, Link\u00f6ping University , Link\u00f6ping, Sweden"},{"name":"Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[{"name":"Nephrology and Kidney Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR) , Barcelona , Spain"},{"name":"Nephrology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sester","sequence":"additional","affiliation":[{"name":"Department of Transplant and Infection Immunology, Institute of Infection Medicine, Saarland University , Homburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge , UK"},{"name":"Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge University Hospitals , Cambridge , UK"},{"name":"Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck , Innsbruck , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"2023111001032573900_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2215\/CJN.05900420","article-title":"Infection-related acute care events among patients with glomerular disease","volume":"15","author":"Glenn","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023111001032573900_bib2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"2023111001032573900_bib3","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfac052","article-title":"Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS","volume":"37","author":"Stevens","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023111001032573900_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13741","article-title":"Vaccination in patients with chronic kidney disease-review of current recommendations and recent advances","volume":"26","author":"Ma","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"2023111001032573900_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO Hepatitis C in CKD guideline: welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int"},{"key":"2023111001032573900_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.15971020","article-title":"Long-term infectious complications of kidney transplantation","volume":"17","author":"Agrawal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023111001032573900_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ndt\/gfaa267","article-title":"Steroids as treatment for glomerulonephritis: time for a rethink","volume":"37","author":"Hendra","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023111001032573900_bib8","doi-asserted-by":"crossref","first-page":"e004100","DOI":"10.1136\/bmjopen-2013-004100","article-title":"Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review","volume":"4","author":"McDonald","year":"2014","journal-title":"BMJ Open"},{"key":"2023111001032573900_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-022-01829-y","article-title":"Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2023111001032573900_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","article-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases","volume":"58","author":"Wijetilleka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023111001032573900_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2023111001032573900_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023111001032573900_bib13","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cNet state of immunosuppression","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023111001032573900_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1681\/ASN.2021091257","article-title":"Secondary immunodeficiency related to kidney disease (SIDKD)-definition, unmet need, and mechanisms","volume":"33","author":"Steiger","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023111001032573900_bib15","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/crj.12961","article-title":"The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients","volume":"12","author":"Korkmaz Ekren","year":"2018","journal-title":"Clin Respir J"},{"key":"2023111001032573900_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023111001032573900_bib17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023111001032573900_bib18","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"2023111001032573900_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2023111001032573900_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023111001032573900_bib21","author":"World Health Organization"},{"key":"2023111001032573900_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"2023111001032573900_bib23","doi-asserted-by":"crossref","first-page":"e000484","DOI":"10.1136\/rmdopen-2017-000484","article-title":"Pneumococcal vaccination in autoimmune rheumatic diseases","volume":"3","author":"R\u00e1k\u00f3czi","year":"2017","journal-title":"RMD Open"},{"key":"2023111001032573900_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2215\/CJN.03390318","article-title":"High-dose seasonal influenza vaccine in patients undergoing dialysis","volume":"13","author":"Miskulin","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023111001032573900_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/j.ajkd.2019.06.014","article-title":"Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation","volume":"75","author":"Krueger","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023111001032573900_bib26","article-title":"Innovative anti-pneumococcal vaccine strategies versus standard vaccination","volume":"74","author":"Terrier","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023111001032573900_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023111001032573900_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01755-17","article-title":"Complement C5a Receptor 1 exacerbates the pathophysiology of N. meningitidis sepsis and is a potential target for disease treatment","volume":"9","author":"Herrmann","year":"2018","journal-title":"mBio"},{"key":"2023111001032573900_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"2023111001032573900_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10096-020-03814-x","article-title":"Thirty years of CMV seroprevalence-a longitudinal analysis in a German university hospital","volume":"39","author":"Hoehl","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023111001032573900_bib31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2023111001032573900_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023111001032573900_bib33","doi-asserted-by":"crossref","first-page":"ofac492.1897","DOI":"10.1093\/ofid\/ofac492.1897","article-title":"Safety and efficacy of letermovir (LET) versus valganciclovir (VGCV) for prevention of cytomegalovirus (CMV) disease in kidney transplant recipients (KTRs): a phase 3 randomized study","volume":"9","author":"Limaye","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023111001032573900_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0961203316671817","article-title":"Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problem","volume":"26","author":"Berman","year":"2017","journal-title":"Lupus"},{"key":"2023111001032573900_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s42358-019-0055-y","article-title":"Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review","volume":"59","author":"Choo","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2023111001032573900_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13063-016-1482-2","article-title":"Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial","volume":"17","author":"Chanouzas","year":"2016","journal-title":"Trials"},{"key":"2023111001032573900_bib37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/23744235.2019.1648855","article-title":"Risk-stratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants","volume":"51","author":"Lim","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2023111001032573900_bib38","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/cid\/cit521","article-title":"Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients","volume":"57","author":"Durand","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023111001032573900_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12969-016-0095-3","article-title":"Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression","volume":"14","author":"Leuvenink","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2023111001032573900_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ckj\/sfs036","article-title":"Chickenpox infection after renal transplantation","volume":"5","author":"Kaul","year":"2012","journal-title":"Clin Kidney J"},{"key":"2023111001032573900_bib41","article-title":"Risk factors for herpes zoster in patients with chronic kidney disease: a case-control study","volume":"9","author":"Li","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2023111001032573900_bib42","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023111001032573900_bib43","doi-asserted-by":"crossref","first-page":"e13566","DOI":"10.1111\/ijcp.13566","article-title":"Risk of herpes zoster among patients with predialysis chronic kidney disease in a cohort study in Taiwan","volume":"74","author":"Lai","year":"2020","journal-title":"Int J Clin Pract"},{"key":"2023111001032573900_bib44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2340\/00015555-1454","article-title":"Lymphopaenia, anti-Ro\/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus","volume":"93","author":"Hu","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"2023111001032573900_bib45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0961203320923739","article-title":"Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies","volume":"29","author":"Mok","year":"2020","journal-title":"Lupus"},{"key":"2023111001032573900_bib46","doi-asserted-by":"crossref","first-page":"e000574","DOI":"10.1136\/lupus-2021-000574","article-title":"Herpes zoster in SLE: prevalence, incidence and risk factors","volume":"9","author":"Kwan","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2023111001032573900_bib47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023111001032573900_bib48","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.06.012","article-title":"Herpes zoster in immunocompromised patients: incidence, timing, and risk factors","volume":"118","author":"Wung","year":"2005","journal-title":"Am J Med"},{"key":"2023111001032573900_bib49","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ekir.2021.02.024","article-title":"Systematic review and meta-analysis of herpes zoster vaccine in patients with CKD","volume":"6","author":"Hamad","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023111001032573900_bib50","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"Dagnew","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023111001032573900_bib51","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023111001032573900_bib52","doi-asserted-by":"crossref","first-page":"978203","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"2023111001032573900_bib53","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients","volume":"38","author":"Racine","year":"2020","journal-title":"Vaccine"},{"key":"2023111001032573900_bib54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40264-021-01076-w","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials","volume":"44","author":"L\u00f3pez-Fauqued","year":"2021","journal-title":"Drug Saf"},{"key":"2023111001032573900_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","article-title":"Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the guidelines of the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus","volume":"101","author":"Henze","year":"2022","journal-title":"Ann Hematol"},{"key":"2023111001032573900_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12879-020-05656-6","article-title":"Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program","volume":"21","author":"Gans","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2023111001032573900_bib57","doi-asserted-by":"crossref","first-page":"100242","DOI":"10.1016\/j.infpip.2022.100242","article-title":"Post-exposure prophylaxis to prevent varicella in immunocompromised children","volume":"4","author":"Yamaguchi","year":"2022","journal-title":"Infect Prev Pract"},{"key":"2023111001032573900_bib58","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","article-title":"Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus","volume":"72","author":"Lagrou","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023111001032573900_bib59","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023111001032573900_bib60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40674-017-0082-y","article-title":"Avoidance of harm from treatment for ANCA-associated vasculitis","volume":"3","author":"King","year":"2017","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2023111001032573900_bib61","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023111001032573900_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023111001032573900_bib63","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023111001032573900_bib64","doi-asserted-by":"crossref","first-page":"152106","DOI":"10.1016\/j.semarthrit.2022.152106","article-title":"Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus","volume":"57","author":"Boone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2023111001032573900_bib65","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/nep.14119","article-title":"Infectious complications in adult patients with idiopathic minimal change nephrotic syndrome undergoing immunosuppressive therapy","volume":"27","author":"Hsu","year":"2022","journal-title":"Nephrology (Carlton)"},{"key":"2023111001032573900_bib66","doi-asserted-by":"crossref","first-page":"152154","DOI":"10.1016\/j.semarthrit.2022.152154","article-title":"Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?","volume":"58","author":"Anumolu","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2023111001032573900_bib67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with iga nephropathy: the testing randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2023111001032573900_bib68","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","article-title":"Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease","volume":"36","author":"Heybeli","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023111001032573900_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2023111001032573900_bib70","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"key":"2023111001032573900_bib71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ndt\/gfac039","article-title":"A real world comparison of HepB (Engerix-B\u00ae) and HepB-CpG (Heplisav-B\u00ae) vaccine seroprotection in patients receiving maintenance dialysis","volume":"38","author":"Manley","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2023111001032573900_bib72","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s12879-019-4300-0","article-title":"Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"19","author":"Yamaguchi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023111001032573900_bib73","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.amjms.2019.10.008","article-title":"Risk factors associated with invasive fungal infections in kidney transplant patients","volume":"359","author":"Leitheiser","year":"2020","journal-title":"Am J Med Sci"},{"key":"2023111001032573900_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad080\/51300645\/gfad080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/Supplement_2\/ii40\/52946071\/gfad080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/Supplement_2\/ii40\/52946071\/gfad080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T01:04:31Z","timestamp":1699578271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/Supplement_2\/ii40\/7176079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":74,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad080","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,22]]}}}